hotspot -WSS

hotspot

author：explore 2025-08-26 23:48:50 - browse：8

This image provided by Novo Nordisk in January 2023, shows packaging for the company's Wegovy drug. — Novo Nordisk via AP

PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in a landmark cardiovascular trial that affirms the treatment offers health benefits beyond weight loss.

The company in August had announced that in this trial, called Select, Wegovy reduced the overall rate of major heart problems — heart attacks, stroke, or cardiovascular-related death — by 20%. That finding, which was the primary outcome the trial set out to study, was stronger than many were expecting and led Novo’s stock to surge.

But details of the study, including risk reductions for each specific heart complication, were not released until Saturday, when they were presented here — before a standing-room only crowd — as the first major session of the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Health insurers say they are turning to AI to cut costs, improve care

focus

WSS

iTeos Therapeutics debuts first data on TIGIT

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

What should King Charles tell the public about his cancer?

Health insurers say they are turning to AI to cut costs, improve care

Biogen Alzheimer’s drug launch off to slow start

Gilead might be held responsible for not developing a drug

Wikipedia

hotspot

hotspot

DIEP, the 'gold standard' of breast reconstruction, is under threat

Focused ultrasound for uterine fibroids: an uphill battle

Guidelines to prevent youth baseball injuries need more muscle

Health insurers say they are turning to AI to cut costs, improve care

Walensky prepares to leave CDC — and Congress — behind

Focused ultrasound for uterine fibroids: an uphill battle

Medicare proposal to cover medical devices draws a mixed reaction

Gilead might be held responsible for not developing a drug

Activists slam private health insurers over coverage restrictions

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

knowledge

Report: NIH

Vaccine advisory panel ACIP left half staffed by HHS

Readout Newsletter: Insmed, Asahi Kasei, Agios, Royalty Pharma

'Revelatory' study finds a smoking impact that remains after quitting

KalVista pill reduced swelling 'attacks' caused by genetic disease

Scientists successfully use ultrasound imaging to map brain activity

focus

hotspot

knowledge

Wikipedia